Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Role of Neurotransmitters in Memory01:23

Role of Neurotransmitters in Memory

2.4K
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
 Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.4K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

503
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
503
Amyloid Fibrils03:03

Amyloid Fibrils

11.5K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.5K
Amyloid Fibrils03:03

Amyloid Fibrils

6.2K
6.2K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

The collection of speech data for the assessment of cognition remotely: Balancing ethical and practical challenges.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Spiro-Linked Polyketides from Cultures of <i>Westerdykella dispersa</i> Ca4-13 as Inhibitors of iNOS-Associated Neuroinflammation.

Journal of natural products·2026
Same author

Benzydamine Attenuates Matrix Metalloproteinase-9 Expression Through Inhibition of ERK MAPK in Activated Human Monocytic Cells Under Hyperglycemic Condition.

Mediators of inflammation·2026
Same author

Evaluating physicians' teaching perspectives and demonstration of core competencies in clinical shadowing.

BMC medical education·2025
Same author

Aging-associated immune signature as a predictor of mortality in end-stage renal disease: results from the longitudinal iESRD study.

Immunity & ageing : I & A·2025
Same author

Anti-herpetic treatment reduces dementia risk: A systematic review and meta-analysis.

Journal of Alzheimer's disease : JAD·2025
Same journal

Stage-dependent relationship between sleep duration and cortical tau deposition in cognitively impaired individuals: A cross-sectional study.

Journal of Alzheimer's disease : JAD·2026
Same journal

Multilayer brain connectivity and long-term cognitive changes in individuals at risk for Alzheimer's disease.

Journal of Alzheimer's disease : JAD·2026
Same journal

The creation and verification of a detection model for mild cognitive impairment by employing eye-tracking and gait metrics.

Journal of Alzheimer's disease : JAD·2026
Same journal

Compartment-specific analysis reveals disrupted astrocytic calcium transients in anesthetized Alzheimer's disease mice.

Journal of Alzheimer's disease : JAD·2026
Same journal

<i>APOE</i> ε4-specific associations between agitation, cerebrospinal fluid biomarkers, and cognitive decline in cognitively impaired patients.

Journal of Alzheimer's disease : JAD·2026
Same journal

Depressive-cognitive interactions modulate amygdala and hippocampus functional connectivity in mild cognitive impairment.

Journal of Alzheimer's disease : JAD·2026
関連記事をすべて見る

関連する実験動画

Updated: Jan 8, 2026

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
07:28

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

4.5K

アミロイド負荷、コリン作動性完全性、および認知機能の関係

Li-Hua Lee1, Chia-Ju Chou1, Yao-Chia Shih2

  • 1Department of Neurology, Cardinal Tien Hospital, New Taipei City, Taiwan.

Journal of Alzheimer's disease : JAD
|December 22, 2025
PubMed
まとめ
この要約は機械生成です。

コリン作動性白質完全性は、初期アルツハイマー病におけるアミロイド蓄積と関連し、認知機能に影響を与える。この関連は、アポリポタンパク質E4遺伝子の非キャリアにおいてより顕著である。

キーワード:
アルツハイマー病アミロイド負荷アポリポタンパク質E4キャリアコリン作動性完全性認知

さらに関連する動画

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.6K
Intracerebroventricular Injection of Amyloid-&#946; Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

44.1K

関連する実験動画

Last Updated: Jan 8, 2026

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
07:28

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

4.5K
Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.6K
Intracerebroventricular Injection of Amyloid-&#946; Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

44.1K

科学分野:

  • 神経科学
  • 放射線学
  • 老年医学

背景:

  • アミロイド蓄積とコリン作動性白質変性は、初期アルツハイマー病（AD）の特徴である。
  • AD発症におけるアミロイド負荷とコリン作動性経路完全性との正確な関係は完全には理解されていない。

研究 の 目的:

  • 初期ADにおけるアミロイド蓄積、コリン作動性白質経路完全性、および認知パフォーマンスとの関連を調査すること。
  • アポリポタンパク質E4（APOE4）遺伝子型がこれらの関係にどのように影響するかを検討すること。

主な方法:

  • 109人の参加者（対照群37人、初期AD群72人）の横断研究。
  • 神経心理学的検査（MMSE、CDR-SB、言語流暢性）。
  • コリン作動性白質完全性のための拡散テンソル画像法（DTI）およびアミロイド負荷のためのアミロイド陽電子放出断層撮影（PET）。

主要な成果:

  • アミロイド負荷とコリン作動性完全性は、全参加者において独立して認知パフォーマンスと関連していた。
  • 初期ADにおいて、アミロイド負荷はMMSEと相関し、コリン作動性完全性はすべての認知測定値と相関していた。
  • アミロイド負荷とコリン作動性完全性は、APOE4非キャリアでのみ有意に相関していた。

結論:

  • アミロイド負荷の影響を受けるコリン作動性白質完全性は、初期アルツハイマー病の特異的な画像バイオマーカーとして機能する可能性がある。
  • この関連は、APOE4遺伝子変異を持たない個人において特に顕著である。